This represents a huge step towards creating powerful biocomputers
. Controlling gene expression through gene switches based on a model borrowed from the digital world has long been one of the primary objectives of synthetic biology.
is a privately held biotechnology company Orchid is fulfilling unmet medical needs through its proprietary pharmacogenetics and microfluidics platform technologies designed to accelerate the discovery and development of novel therapeutic and bioanalytic products.
The model "biocomputer
," which is roughly the size of a book, is powered by Adenosine triphosphate (ATP) - dubbed the "molecular unit of currency."
The recent work of Russian physicists has further advanced the hypothesis that down to DNA and chromosomes, the human body represents a nonlocal holographic biocomputer
carrying out its functions via energy-wave phenomenon with speed far exceeding one of chemical reactions, equal to and even exceeding the speed of light.
Princeton, NJ 1/6/00-Orchid Biocomputer
has acquired GeneScreen, a genetic diversity analysis service.
"Adverse drug response, lack of response, and predisposition to disease are the largest unmet medical needs yet to face health care," says Dale Pfost, CEO of Orchid Biocomputer
, a Princeton, N.J., company that markets pharmacogenetic products and services.
and SNP Consortium have entered into an agreement for Orchid to perform validation and quality control testing on genetic markers identified by SNP...Galileo announced that Andlinger Capital XIII purchased one million shares of company common stock as part of an equity financing agreement announced earlier this year.
In a Montreux presentation by Orchid Biocomputer
, Princeton, N.J., S.
and Beckman Coulter to Collaborate Princeton, NJ, 3/22/99-Orchid Biocomputer
and Beckman Coulter entered a collaboration to develop a high-throughput technology for conducting massive single nucelotide polymorphism genotyping.
Little wonder also that pharmaceutical companies are scrambling to offer billions of dollars to join forces with the emerging giants of the new industry, such as Affymetrix, Santa Clara, Calif., Nanogen, San Diego, Calif., and Orchid Biocomputer
, Princeton, N.J.
recently announced that it had entered into a five-year collaborative research agreement with Advanced BioAnalytical Services, Ithaca, N.Y., to develop novel microfluidic chip technologies.
Affymetrix also entered an agreement with Research Genetics, by which Affymetrix will sell GeneChip arrays to Research Genetics, who will then offer screening and data analysis services based on the GeneChip platform...Boston Probes and Millipore entered a strategic alliance to jointly develop peptide nucleic acid probe-based tests for Millipore to distribute...Orchid Biocomputer
and Motorola entered a $15 million collaboration to enhance Orchid's microfluidic chips and further develop the technology.